FDA releases draft guidance on master protocol studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has published a draft guidance titled “Master Protocols–Efficient Clinical Trial Design Strategies to Expedite Development of Cancer Drugs and Biologics.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login